ELOXATIN
LOE ApproachingNDAINTRAVENOUSINJECTABLEPriority Review
Approved
Aug 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELOXATIN is a small-molecule platinum-based chemotherapy agent approved by the FDA in 2002. Specific indications and mechanism of action data are not available in the current dataset. It is administered intravenously as an injectable formulation.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential downsizing or transition of the brand support team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
Started Sep 2007
38 enrolled
Carcinoma, Hepatocellular
Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer
Started Dec 2006
79 enrolled
Colorectal CancerLiver Metastases
TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
Started Mar 2006
132 enrolled
Ovarian Cancer
A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC
Started Nov 2005
69 enrolled
Non-Small Cell Lung Cancer
Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer
Started Dec 2004
24 enrolled
Colorectal Cancer
Worked on ELOXATIN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.